Market news

Progyny has delivered a mixed ride for shareholders, with the stock climbing over the past year but still showing a steep decline over five years. This puts a sharper spotlight on what investors are really paying for its earnings today. With that backdrop, the key issue is whether the current share price around US$27 fairly reflects the company’s profit engine. Over the past 5 years, Progyny’s share price has fallen 57.5%, which raises the question of whether the market is reassessing how...

Kevin K Gordon, Director, on September 10, 2026, sold 11,500 shares in Progyny (PGNY) for $321,358.

Let’s dig into the relative performance of Progyny (NASDAQ:PGNY) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://inves

What employees really want are fertility benefits, and there’s a market for providing them that’s underserved. Progyny provides family-focused services to about 7 million patients at more than 600 companies, but Wells Fargo sees a potential market of 156 million. The decade-old company made nearly $1.3 billion in revenue in the past fiscal year, up 10%, as it continued expanding beyond basic fertility services. Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks.

Progyny is set to benefit from several structural tailwinds, including catalysts that should help it court more clients, according to Wells Fargo.

Progyny (NASDAQ:PGNY) CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management’s confidence in its outlook for the remainder of the year. Spea

Progyny’s second quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street expectations. CEO Peter Anevski attributed the quarter’s growth to continued demand from employers for family building and women’s health solutions, emphasizing strong retention and early client commitments. Management noted that higher engagement levels and operational efficiencies contributed to margin expansion, while a more pronounced summer

Progyny (PGNY) has an average rating of buy and mean price target of $33.73, according to analysts p

Detailed price information for Progyny Inc (PGNY-Q) from The Globe and Mail including charting and trades.

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

Detailed price information for Progyny Inc (PGNY-Q) from The Globe and Mail including charting and trades.

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (NASDAQ:PGNY) reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season. Chief Executive Officer Pete Anevs

Progyny Inc (PGNY) reports strong Q2 2026 results with record quarterly revenue and adjusted EBITDA, while navigating summer seasonality and investing in future growth initiatives.

Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Progyny (PGNY) delivered earnings and revenue surprises of +7.84% and +0.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 5.3% year on year to $350.5 million. On the other hand, next quarter’s revenue guidance of $340 million was less impressive, coming in 3% below analysts’ estimates. Its non-GAAP profit of $0.55 per share was 6.2% above analysts’ consensus estimates.

Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDARobust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building SolutionsValue Returned to Shareholders Through the Repurchase of Over 2 Million Shares Under Current Authorization NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the th

Detailed price information for Progyny Inc (PGNY-Q) from The Globe and Mail including charting and trades.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United Stat

Disposition reduced her direct holdings by 5% through a combination of Rule 10b5-1 plan sales and tax-withholding shares, leaving her with a $2.26 million stake.